Drugs Containing Excipient (Inactive Ingredient) HYDROGENATED OLIVE OIL

« Back to Dashboard

Generic drugs containing HYDROGENATED OLIVE OIL excipient

Company	Ingredient	NDC	Excipient
PD-Rx Pharmaceuticals Inc	flecainide acetate	72789-385	HYDROGENATED OLIVE OIL
Bayshore Pharmaceuticals LLC	flecainide acetate	76385-145	HYDROGENATED OLIVE OIL

Hydrogenated Olive Oil Excipient Market Dynamics and Financial Trajectory

Last updated: August 18, 2026

Hydrogenated olive oil is a niche lipid-based excipient and formulation ingredient with limited public market disclosure. Its commercial outlook is driven by demand for semisolid dosage forms, lipid-based delivery systems, controlled release, and plant-derived pharmaceutical ingredients. Public sources do not identify a standalone global market size or supplier revenue category for hydrogenated olive oil. Financial analysis therefore relies on excipient-market growth, formulation demand, raw-material economics, regulatory qualification, and supplier positioning.

What is hydrogenated olive oil used for in pharmaceutical formulations?

Hydrogenated olive oil is produced by catalytic hydrogenation of olive-derived triglycerides. Hydrogenation raises melting point, improves oxidative stability, and converts a liquid oil into a waxy or semisolid material.

Potential pharmaceutical functions include:

Function	Formulation relevance
Lipid matrix former	Supports sustained-release and multiparticulate formulations
Consistency agent	Modifies hardness, spreadability, and melting behavior in creams and ointments
Emollient or vehicle	Used in topical and dermatological products
Lubricant or processing aid	May reduce sticking in selected solid-dose manufacturing processes
Lipid carrier	Can be incorporated into lipid-based drug-delivery systems
Stabilizer	Improves resistance to oxidation compared with unhydrogenated olive oil

Hydrogenated olive oil should be distinguished from glyceryl behenate, hydrogenated cottonseed oil, hydrogenated palm oil, and sorbitan olivate. These materials can compete for similar formulation functions but have different fatty-acid profiles, melting ranges, compendial status, and supplier histories.

How large is the hydrogenated olive oil excipient market?

No major public market report isolates hydrogenated olive oil as a separate pharmaceutical-excipient revenue segment. Suppliers generally group it with specialty lipids, waxes, botanical excipients, cosmetic ingredients, or formulation aids.

The addressable market is best divided into four segments:

1. Pharmaceutical creams, ointments, and topical delivery systems.
2. Oral lipid matrices and modified-release formulations.
3. Nutraceutical and supplement dosage forms.
4. Personal-care products, which are likely to represent the largest demand pool for hydrogenated olive-oil derivatives.

Pharmaceutical demand is smaller than cosmetic demand but has higher qualification value. Once a material is incorporated into a validated formulation, switching costs can include stability studies, process revalidation, regulatory filings, and supplier requalification.

Market-growth drivers

The main demand drivers are:

• Growth in topical and dermatological products.
• Use of lipid excipients in poorly water-soluble drug formulations.
• Preference for plant-derived ingredients in some product categories.
• Demand for low-odor, oxidation-resistant emollients.
• Expansion of specialty generics and reformulated products.
• Greater use of semisolids, liposomes, lipid nanoparticles, and other delivery platforms.

Market constraints

Commercial adoption is constrained by:

• Limited public pharmaceutical compendial recognition.
• Competition from better-established lipid excipients.
• Batch variability in botanical feedstocks.
• Need to control peroxide value, acid value, moisture, residual catalyst, and fatty-acid composition.
• Limited published pharmaceutical performance data.
• Potential difficulty qualifying the material for regulated drug applications.

What is the financial trajectory for hydrogenated olive oil excipients?

The expected financial trajectory is specialty-ingredient growth rather than rapid volume expansion. Pricing power depends on pharmaceutical grade, documentation, formulation performance, and supply continuity.

Financial factor	Expected effect
Olive-oil feedstock prices	Directly affect cost of goods
Hydrogenation energy and catalyst costs	Increase conversion cost
Pharmaceutical-grade testing	Raises unit cost but supports premium pricing
Small production volumes	Limit manufacturing economies of scale
Botanical traceability	Adds procurement and quality expense
Cosmetic demand	Provides volume support
Pharmaceutical qualification	Creates higher-margin, stickier accounts
Substitute excipients	Limits long-term price expansion

A supplier selling hydrogenated olive oil primarily into cosmetics will typically compete on sensory performance, purity, origin, and price. A pharmaceutical supplier can compete on technical documentation, lot consistency, regulatory support, and change-control discipline.

The most attractive financial model is a dual-market strategy: use personal-care demand to support manufacturing scale while developing pharmaceutical customers that pay for higher specifications and technical service.

Margin profile

Pharmaceutical excipient margins can exceed commodity vegetable-oil margins when the supplier provides:

• Controlled polymorphism or melting behavior.
• Narrow specification ranges.
• Validated analytical methods.
• Animal-origin-free documentation.
• Residual-solvent and elemental-impurity controls.
• Stability data.
• Regulatory support packages.
• Consistent global supply.

Hydrogenated olive oil does not automatically command a pharmaceutical premium. The premium arises from qualification and documentation, not from hydrogenation alone.

Which companies supply or compete with hydrogenated olive oil?

Publicly visible competition is fragmented. Relevant competitors include manufacturers and distributors of:

• Hydrogenated vegetable oils.
• Glyceryl behenate.
• Glyceryl palmitostearate.
• Hard fats and pharmaceutical waxes.
• Hydrogenated castor oil.
• Hydrogenated cottonseed oil.
• Medium-chain triglycerides.
• Beeswax and synthetic waxes.
• Sorbitan esters and olive-derived emulsifiers.

Named pharmaceutical excipient suppliers with adjacent lipid portfolios include Gattefossé, BASF, Croda, IOI Oleo, ABITEC, Lubrizol, Peter Greven, and associated regional distributors. Their portfolios do not establish that every company supplies hydrogenated olive oil specifically. They compete through overlapping lipid-excipient technologies.

The strongest competitive substitutes are usually:

Substitute	Relative advantage
Glyceryl behenate	Strong pharmaceutical history in sustained-release tablets
Hydrogenated cottonseed oil	Established use as a tablet lubricant and binder in some markets
Hydrogenated castor oil	High melting point and established wax functionality
Glyceryl palmitostearate	Useful matrix former and lubricant
Medium-chain triglycerides	Liquid carrier and bioavailability-enhancement applications
Hard fats	Well-established suppository and semisolid uses

What is the FDA regulatory status of hydrogenated olive oil?

Hydrogenated olive oil does not have the same broadly recognized pharmaceutical status as several established excipients listed in the FDA Inactive Ingredient Database. FDA acceptance is product-specific and depends on dosage form, route, concentration, and prior precedent.

The relevant regulatory path generally involves:

1. Confirming the exact chemical identity and grade.
2. Reviewing FDA Inactive Ingredient Database entries.
3. Assessing USP-NF, Ph. Eur., BP, or other compendial status.
4. Providing manufacturing and impurity information.
5. Demonstrating compatibility, stability, and performance in the finished product.
6. Addressing novel-excipient issues if the material lacks adequate U.S. drug-use precedent.

FDA’s Inactive Ingredient Database does not function as a blanket approval of an excipient for every route or concentration. A listing, where applicable, is tied to specific use conditions and dosage forms.[1]

European regulatory position

In Europe, excipient acceptability is assessed through the finished medicinal product dossier and applicable quality requirements. The European Medicines Agency expects applicants to provide appropriate information on excipient quality, function, safety, and control strategy.[2]

A supplier’s pharmaceutical-grade documentation should normally address:

• Identity and composition.
• Manufacturing process.
• Specifications.
• Analytical methods.
• Residual metals and catalyst residues.
• Microbial quality.
• Oxidation parameters.
• Allergen and GMO status.
• TSE/BSE status.
• Packaging and storage.
• Stability and retest period.

What formulations are protected or differentiated by hydrogenated olive oil?

Hydrogenated olive oil is more likely to support formulation know-how than a broad, enforceable composition patent.

Potentially differentiable technologies include:

• Controlled-release lipid matrices.
• Topical creams with defined melting and spreadability profiles.
• Suppository bases.
• Lipid microparticles.
• Solid lipid nanoparticles.
• Nanoemulsions and self-emulsifying systems.
• Botanical drug or nutraceutical delivery systems.
• Combinations with surfactants, phospholipids, or waxes.

A patent may claim a drug formulation containing hydrogenated olive oil, a specified concentration range, a particle-size distribution, a manufacturing process, or a therapeutic use. The commercial value of such claims depends on whether the ingredient is essential to the claimed performance and whether substitutes can avoid infringement.

How strong is the patent estate for hydrogenated olive oil?

The standalone patent estate appears structurally weak compared with branded-drug patent portfolios. Hydrogenated olive oil is an ingredient class, and broad claims directed only to the material may face prior-art and obviousness challenges.

The stronger intellectual-property positions are likely to involve:

• Proprietary grades with tightly controlled physical properties.
• Defined fatty-acid or triglyceride distributions.
• Drug-specific delivery systems.
• Process conditions producing a distinct solid form.
• Combinations with active pharmaceutical ingredients.
• Manufacturing methods that improve stability or release.
• Trade-secret specifications and process controls.

Patent searches should distinguish “hydrogenated olive oil” from:

• Hydrogenated olive oil unsaponifiables.
• Hydrogenated olive-oil fatty acids.
• Hydrogenated olive-oil waxes.
• Olive-derived emulsifiers.
• Hydrogenated triglycerides containing olive-oil fractions.

These are chemically and commercially different categories. No material basis exists for identifying a dominant Orange Book patent estate for hydrogenated olive oil itself.

Are there Paragraph IV challenges or Orange Book listings?

Paragraph IV litigation is generally associated with abbreviated new drug applications challenging patents listed in the FDA Orange Book for an approved drug. Hydrogenated olive oil, as an excipient, is not itself an Orange Book-listed drug product.

Accordingly:

• There is no standalone Orange Book exclusivity period for hydrogenated olive oil.
• There is no independent Paragraph IV market-entry timeline for the excipient.
• Litigation risk arises through finished drug products that use the ingredient.
• A formulation patent may be listed for a drug if it satisfies applicable Orange Book requirements.
• Supplier disputes are more likely to involve contracts, specifications, trade secrets, or formulation patents than excipient exclusivity.

The relevant patent risk must be assessed at the finished-product level.

When does hydrogenated olive oil lose exclusivity?

Hydrogenated olive oil has no intrinsic regulatory exclusivity period. Exclusivity may attach to a finished pharmaceutical product using the ingredient through:

• New chemical entity exclusivity.
• New formulation or new indication exclusivity.
• Orphan-drug exclusivity.
• Pediatric exclusivity.
• Valid patents covering the finished formulation or method of use.

Those periods belong to the drug product, not to hydrogenated olive oil. Generic entry depends on the patent and exclusivity profile of the finished medicine, as well as the substitutability of the excipient in the approved formulation.

What manufacturing and supply-chain barriers affect pricing?

Hydrogenation requires control of temperature, pressure, catalyst loading, mixing, filtration, and post-reaction purification. Pharmaceutical production adds requirements for validated cleaning, traceability, change control, and contamination prevention.

Key supply risks include:

• Variability in olive cultivars and refining history.
• Seasonal feedstock changes.
• Oxidation during storage.
• Catalyst carryover.
• Inconsistent solid-fat content.
• Differences in melting point and congealing behavior.
• Packaging interactions.
• Limited qualified manufacturing sites.

Geographic coverage is also relevant. Olive-oil supply is concentrated in the Mediterranean basin, while pharmaceutical excipient processing and distribution may occur in Europe, North America, and Asia. A supplier with one qualified hydrogenation site may create a single-source risk for regulated customers.

How does hydrogenated olive oil compare with established pharmaceutical lipids?

Criterion	Hydrogenated olive oil	Glyceryl behenate	Hydrogenated castor oil	Hydrogenated cottonseed oil
Plant-derived positioning	High	High	High	High
Pharmaceutical precedent	Limited or product-specific	Stronger	Established in selected uses	Established in selected uses
Oxidative stability	Improved versus olive oil	Generally strong	Strong	Strong
Botanical variability	Material	Lower after standardization	Material	Material
Controlled-release utility	Potential	Strong	Moderate to strong	Moderate
Regulatory familiarity	Lower	Higher	Moderate	Moderate
Price premium potential	Niche	Established	Niche	Niche
Substitution risk	High	Lower in validated applications	Moderate	Moderate

Hydrogenated olive oil is most competitive where olive-derived origin, sensory properties, or a specific melting profile is commercially important. It is less competitive where formulation developers prioritize extensive pharmaceutical precedent and globally harmonized excipient standards.

What generic launch risks exist for products containing hydrogenated olive oil?

Generic manufacturers can usually substitute excipients only if the revised formulation satisfies bioequivalence, stability, quality, and regulatory requirements. For topical products, changes in vehicle composition can affect drug release, skin permeation, rheology, and local tolerability.

Generic-entry risks include:

• Difficulty matching the reference product’s release profile.
• Need to reproduce semisolid microstructure.
• Supplier qualification delays.
• Limited access to the innovator’s formulation know-how.
• Patent claims covering excipient combinations.
• Regulatory scrutiny of changes to inactive ingredients.
• Reliance on a small number of qualified suppliers.

The excipient can therefore create formulation friction without creating independent exclusivity.

Are licensing deals publicly disclosed?

No major publicly disclosed licensing transaction centered specifically on hydrogenated olive oil as a pharmaceutical excipient is established in the public record. Commercial arrangements are more likely to involve:

• Private-label supply.
• Regional distribution.
• Custom manufacturing.
• Long-term quality agreements.
• Formulation development contracts.
• Technology transfer for lipid-delivery platforms.

The economic value of these agreements is usually embedded in broader excipient or drug-development contracts rather than reported separately.

What is the commercial outlook through the next five years?

The base-case outlook is moderate growth in specialty demand, with pharmaceutical uptake lagging cosmetic and nutraceutical use.

Period	Expected market condition
Near term	Demand supported by cosmetics, topical products, and specialty lipid systems
Mid term	Selective pharmaceutical adoption where oxidation resistance or plant origin improves formulation value
Longer term	Growth depends on compendial recognition, published performance data, and multi-site supply

Revenue upside is strongest for suppliers that convert hydrogenated olive oil from a commodity-like ingredient into a qualified platform excipient. That requires standardization, regulatory files, technical support, and evidence in finished dosage forms.

Key Takeaways

• Hydrogenated olive oil is a niche lipid excipient with limited standalone market disclosure.
• Cosmetic and personal-care applications likely provide the largest volume base.
• Pharmaceutical value depends on qualification, consistency, and formulation performance.
• Glyceryl behenate, hydrogenated castor oil, and hydrogenated cottonseed oil are major substitutes.
• The ingredient has no standalone Orange Book, Paragraph IV, or regulatory exclusivity position.
• Patent value is more likely to arise from drug-specific formulations and manufacturing processes.
• Olive-oil feedstock variability and limited qualified capacity are the main supply-chain risks.
• The strongest financial strategy is a dual-market model combining cosmetic volume with pharmaceutical-grade premium sales.
• Near-term growth is likely to be selective rather than explosive.

FAQs

Is hydrogenated olive oil an approved pharmaceutical excipient?

It can be used in pharmaceutical products when the finished product sponsor establishes appropriate quality, safety, and performance support. It does not have universal approval for every dosage form or route.

Is hydrogenated olive oil the same as hydrogenated castor oil?

No. They are different hydrogenated triglyceride materials with different fatty-acid compositions, melting behavior, manufacturing profiles, and pharmaceutical histories.

Can hydrogenated olive oil improve drug bioavailability?

It may support lipid-based delivery and improve wetting or solubilization for selected poorly water-soluble compounds. The effect is formulation-specific and requires experimental confirmation.

Does hydrogenated olive oil create a barrier to generic competition?

It can increase formulation-development and supplier-qualification costs, especially in topical and modified-release products. It does not independently prevent generic entry.

Which quality tests are most important for pharmaceutical-grade hydrogenated olive oil?

Identity, melting or congealing range, acid value, peroxide value, saponification value, water content, fatty-acid composition, residual catalyst or metals, microbial quality, and stability are central controls.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. European Medicines Agency. (2018). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu/

3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

4. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.

5. U.S. Food and Drug Administration. (2019). Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry. https://www.fda.gov/